A Study of Nystatin in HIV-Infected Patients

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI) administered in an alternating regimen in this patient population.

Key facts

Study ID

NCT00002313

Run by

Argus Pharmaceuticals

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Completed 12 weeks of therapy with intravenous nystatin on protocol FDA 103B.
• No evidence of toxicity or progression of disease on protocol FDA 103B. (See protocol FDA 103B for initial entry requirements.)
• Active drug or alcohol abuse.

Where it is running

• Twelve Oaks Hosp — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.